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For patients with contraindications to chronic oral antico-agulation, new therapeutic approaches have been
developed.1
Transcatheter closure of the left atrial appendage (LAA) is
becoming more common as an interventional therapy to
prevent thromboembolic complications in patients with atrial
fibrillation (AF) and contraindications to chronic oral antico-
agulation. Most of the studies about this new technique
demonstrated its safety as an alternative method to oral
anticoagulation in this group of patients.1 One of the feared
complications is thrombus formation in relation with the
device. To prevent this, patients are medicated with long-term
antiplatelet treatment.1 A case is reported in which a throm-
bus was noted on the left side of an Amplatzer Cardiac Plug
by transesophageal echocardiography, and anticoagulation
had to be started.
Case Report
A 75-year-old man with chronic AF, previous ischemic
stroke, known ischemic cardiomyopathy (with previous cor-
onary bypass grafting surgery after myocardial infarction),
medicated hypertension, diabetes mellitus, and a CHADS2
score of 6 had to stop oral anticoagulation because of
persistent hematuria.In March 2010, a percutaneous closure
of the LAA with a 28-mm Amplatzer Cardiac Plug device
was performed. The procedure to implant the device was free
of complications and had no residual flow at the end. The
patient was on a daily dose of aspirin 100 mg, and 100 U/kg
heparin was added at the beginning of the procedure. He was
asymptomatic under double-antiaggregation therapy with aspirin
and clopidogrel. The 6-month follow-up transesophageal echo-
cardiography revealed autocontrast in the left atrium and a
sessile thrombus (189 mm) located at the left atrial side of
the device (Figure). There was particular concern about
embolization, and intravenous heparin was started (maintain-
ing the activated partial thromboplastin time ratio at 2.5). A
further transesophageal echocardiography performed 1 week
after heparin was started showed no resolution of the thrombus,
which maintained the same dimensions. Transesophageal echo-
cardiography was repeated 3 weeks later and showed reduc-
tion of the thrombus. The patient was started on oral anticoag-
ulation and continued to be stable without any cardiovascular
events. There were no early complications as a result of the
treatment. Unfortunately, he later developed hematuria (with the
need for transfusion support), and anticoagulation had to be
stopped again. He remained assyntomatic.
Discussion
AF is epidemiologically the most common cardiac arrhyth-
mia, and it is responsible for 15% to 20% of all ischemic
strokes.2 Although the potential of warfarin to reduce sys-
temic embolization in AF is well established, its use is
difficult, especially in older patients, because of significant
drug interactions, the need of frequent monitoring of the
international normalized ratio, a very narrow therapeutic
range, and a high risk of bleeding complications. In patients
treated with oral anticoagulation, approximately 44% of
patients have suboptimal therapeutic levels.3 Therefore, alter-
native treatments to prevent stroke in patients with AF are
needed. It is assumed that 90% of clinically apparent
embolisms in AF originate from the LAA. Obliteration of the
LAA might provide an alternative therapy for stroke preven-
tion in patients with AF at high risk of systemic embolization.
Three devices have been specifically designed for LAA
occlusion: the Percutaneous Left Atrial Appendage Trans-
catheter Occlusion (PLAATO), the WATCHMAN LAA
system, and the Amplatzer Cardiac Plug. Devices differ in
design, and their implantation is made by venous access and
transseptal puncture, under local anesthesia. The PLAATO
device has been discontinued for commercial reasons.
Several studies of the percutaneous transcatheter delivery
of dedicated LAA occlusion devices have shown promising
results that offer an alternative to warfarin therapy for
selected patients (those with chronic AF and contraindication
to warfarin therapy).1
In the PLAATO trial,4 a nonrandomized, prospective
study, LAA occlusion was successful in all patients, and there
were no complications or embolic events at 1-month follow-
up. The study demonstrated the safety and effectiveness of
the PLAATO implantation.
Likewise, the recently published Protection in patients with
Atrial Fibrillation (PROTECT-AF) trial,5 comparing closure
of the LAA with the WATCHMAN device with long-term
warfarin therapy, showed that there was a reduction in
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hemorrhagic stroke risk versus warfarin, and all-cause stroke
and all-cause mortality outcomes were not inferior to warfa-
rin. The primary end point was the absence of ischemic and
hemorrhagic stroke, cardiovascular and unexplained death,
and systemic embolism. However, implantation of the
WATCHMAN device causes a significant procedural risk
that must be taken into account, including pericardial effusion
requiring invasive treatment and acute ischemic stroke due to
thromboembolism. There are also some reports of complica-
tions related to the transseptal puncture or device, such as
postimplantation sepsis and device embolization.5 However,
we might think that, as in the occlusion of atrial septal
defects, thrombosis may occur in the implantation process
because of inadequate size, incorrect placement, or instability
of the device, but in these reported complications of the
technique, thrombosis is acute.6
There is no direct comparison between the available
devices. In the literature, most of the studies showed relative
risk reduction of stroke compared with the predicted rate with
the SCHADS2 score.1
The current antithrombotic regimen recommendation differ
between WATCHMEN and Aplatzer cardiac plug device. In
the later, current recommendations after the LAA closure,
patients be medicated with aspirin (81–325 mg) indefinitely
and with clopidogrel (75 mg) for at least 4 to 6 weeks. The
ACTIVE study8 showed the superiority of double-antiplatelet
therapy versus aspirin alone, so these patients should main-
tain double-antiplatelet therapy.
Despite the encouraging results of several studies about
percutaneous LAA exclusion, we are in the learning curve,
and additional studies are needed to verify the safety and
effectiveness of the devices, and to know if the current
practice of treating patients only with double-antiplatelet
therapy before endothelization of the device is sufficient, or if
one should use oral anticoagulation in the first 3 months as is
advised in biological prostheses. As in the present case,
thrombosis might be a rare, but possible complication, and
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Figure. Mid esophageal 2 (chamber view, 90 degrees). Throm-
bus located at the left atrial side of the Amplatzer.
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